Vnitr Lek 2019, 65(2):131-135
Adverse effects of immunoglobulin therapy
- Ústav klinické imunologie a alergologie LF MU a FN u sv. Anny v Brně
Immunoglobulin products contain specific antibodies in IgG class which are directed against wide range of pathogens. These products are obtained from plasma of healthy donors. Immunoglobulin derivates can be administrated by intravenous or subcutaneous route in substitution or immunomodulation indications. The administration can be accompanied by a risk of adverse events. The most common are pyretic reactions, chills, headache, nausea, malaise and muscle pain, nevertheless also severe systemic reactions can occur. Almost one third of the reactions appear during the first administration. The number and severity of reactions depends on administered dose, speed and the application way. Pre-existing comorbidities of the patients and presence of acute infection are also an important risk factors for adverse reactions. Therapy of side effects is mostly symptomatic.
Keywords: adverse events; anaphylaxis; intravenous immunoglobulins; subcutaneous immunoglobulins
Received: March 16, 2018; Published: February 1, 2019 Show citation
References
- Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9(6): 722-728.
Go to original source...
Go to PubMed...
- Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008; 28: 737-764, viii. Dostupné z DOI: <http://dx.doi.org/10.1016/j.iac.2008.06.004>.
Go to original source...
Go to PubMed...
- Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1(8232): 1228-1231.
Go to original source...
Go to PubMed...
- Perez EE, Orange JS, Bonilla F et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol 2017; 139(3S): S1-S46. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2016.09.023>.
Go to original source...
Go to PubMed...
- Gelfand EW. Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs 2005; 28(6): 366-374.
Go to original source...
Go to PubMed...
- Simon HU, Späth PJ. IVIG - mechanisms of action. Allergy 2003; 58(7): 543-552.
Go to original source...
Go to PubMed...
- Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38(1-3): 122-132.
Go to original source...
Go to PubMed...
- Negi VS, Elluru S, Sibéril S et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 2007; 27(3): 233-245. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875-007-9088-9>.
Go to original source...
Go to PubMed...
- Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008; 28: 413-437, x. Dostupné z DOI: <http://dx.doi.org/10.1016/j.iac.2008.01.008>.
Go to original source...
Go to PubMed...
- Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol 2008; 101(2): 114-121; quiz 122-123, 78. Dostupné z DOI: <http://dx.doi.org/10.1016/S1081-1206(10)60197-4>.
Go to original source...
Go to PubMed...
- Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008; 28(4): 803-819. Dostupné z DOI: <http://dx.doi.org/10.1016/j.iac.2008.06.006>.
Go to original source...
Go to PubMed...
- Azizi G, Abolhassani H, Asgardoon MH et al. Managing patients with side effects and adverse events to immunoglobulin therapy. Expert Rev Clin Pharmacol 2016; 9(1): 91-102. Dostupné z DOI: <http://dx.doi.org/10.1586/17512433.2016.1105131>.
Go to original source...
Go to PubMed...
- Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27(3): 171-178. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tmrv.2013.05.004>.
Go to original source...
Go to PubMed...
- Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994; 97(Suppl 1): SS79-83.
- Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999; 21(3): 171-185. Dostupné z DOI: <http://dx.doi.org/10.2165/00002018-199921030-00003>.
Go to original source...
Go to PubMed...
- Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17(4): 241-251.
Go to original source...
- Orbach H, Katz U, Sherer Y et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29(3): 173-184. Dostupné z DOI: <http://dx.doi.org/10.1385/CRIAI:29:3:173>.
Go to original source...
Go to PubMed...
- Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008; 122(6): 1238-1239. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2008.08.033>.
Go to original source...
Go to PubMed...
- Bichuetti-Silva DC, Furlan FP, Nobre FA et al. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. Int Immunopharmacol 2014; 23(2): 442-446. Dostupné z DOI: <http://dx.doi.org/10.1016/j.intimp.2014.09.015>.
Go to original source...
Go to PubMed...
- Berard R, Whittemore B, Scuccimarri R. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol Online J 2012; 10(1): 10. Dostupné z DOI: <http://dx.doi.org/10.1186/1546-0096-10-10>.
Go to original source...
Go to PubMed...
- Bonagura VR, Marchlewski R, Cox A et al. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122(1): 210-212. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2008.04.044>.
Go to original source...
Go to PubMed...
- Pautard B, Hachulla E, Bagot d'Arc M et al. Intravenous immunoglobulin (Endobulin) clinical tolerance: prospective therapeutic follow-up of 142 adults and children. Rev Med Interne 2003; 24(8): 505-513.
Go to original source...
Go to PubMed...
- Brennan VM, Salomé-Bentley NJ, Chapel HM et al. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003; 133(2): 247-251.
Go to original source...
Go to PubMed...
- Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child 2006; 91(8): 651-654. Dostupné z DOI: <http://dx.doi.org/10.1136/adc.2005.078733>.
Go to original source...
Go to PubMed...
- Schroeder HW, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection 2012; 40(6): 601-611. Dostupné z DOI: <http://dx.doi.org/10.1007/s15010-012-0323-9>.
Go to original source...
Go to PubMed...
- Bonilla FA. Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc 2016; 37(6): 426-431.
Go to original source...
Go to PubMed...
- Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007; 21(2): 105-116. Dostupné z DOI: <http://dx.doi.org/10.2165/00063030-200721020-00005>.
Go to original source...
Go to PubMed...
- Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol Pract 2013; 1(6): 558-566. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaip.2013.09.012>.
Go to original source...
Go to PubMed...
- Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007; 96(10): 1474-1478. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1651-2227.2007.00485.x>.
Go to original source...
Go to PubMed...
- Gardulf A, Hammarström L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338(8760): 162-166.
Go to original source...
Go to PubMed...
- Vultaggio A, Azzari C, Milito C et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig 2015; 35(3): 179-185. Dostupné z DOI: <http://dx.doi.org/10.1007/s40261-015-0270-1>.
Go to original source...
Go to PubMed...
- Welch MJ, Stiehm ER. Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin. J Clin Immunol 1983; 3(3): 285-286.
Go to original source...
Go to PubMed...
- Sundin U, Nava S, Hammarström L. Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998; 112(2): 341-346.
Go to original source...
Go to PubMed...
- de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 2000; 20(1): 77-82.
Go to original source...
Go to PubMed...
- Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986; 314(9): 560-564. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM198602273140907>.
Go to original source...
Go to PubMed...
- Barandun S, Kistler P, Jeunet F et al. Intravenous administration of human gamma-globulin. Vox Sang 1962; 7: 157-174.
Go to original source...
- Koistinen J, Heikkilä M, Leikola J. Gammaglobulin treatment and anti-IgA antibodies in IgA-deficient patients. Br Med J 1978; 2(6142): 923-924.
Go to original source...
Go to PubMed...
- Ferreira A, García Rodriguez MC, Fontán G. Follow-up of anti-IgA antibodies in primary immunodeficient patients treated with gamma-globulin. Vox Sang 1989; 56(4): 218-222.
Go to original source...
- Cunningham-Rundles C, Zhou Z, Mankarious S et al. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993; 13(4): 272-278.
Go to original source...
Go to PubMed...
- Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012; 129(3): 628-634.
Go to original source...
Go to PubMed...
- [Centers for Disease Control and Prevention (CDC)]. Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. MMWR Morb Mortal Wkly Rep 1999; 48(24): 518-521.
- Kato E, Shindo S, Eto Y et al. Administration of immune globulin associated with aseptic meningitis. JAMA 1988; 259(22): 3269-3271.
Go to original source...
- Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121(4): 259-262.
Go to original source...
Go to PubMed...
- Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 2003; 60(11): 1736-1737.
Go to original source...
Go to PubMed...
- Wolberg AS, Kon RH, Monroe DM et al. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65(1): 30-34.
Go to original source...
Go to PubMed...
- Quinti I, Pierdominici M, Marziali M et al. European surveillance of immunoglobulin safety-results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. Clin Immunol 2002; 104(3): 231-236.
Go to original source...
Go to PubMed...
- Helbert MR, Bangs C, Bishop M et al. No evidence of asymptomatic variant CJD infection in immunodeficiency patients treated with UK-sourced immunoglobulin. Vox Sang 2016; 110(3): 282-284. Dostupné z DOI: <http://dx.doi.org/10.1111/vox.12358>.
Go to original source...
Go to PubMed...
- Bjøro K, Frøland SS, Yun Z et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331(24): 1607-1611. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199412153312402>.
Go to original source...
Go to PubMed...
- Bresee JS, Mast EE, Coleman PJ et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA 1996; 276(19): 1563-1567.
Go to original source...
Go to PubMed...
- Rossi G, Tucci A, Cariani E et al. Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status. Blood 1997; 90(3): 1309-1314.
Go to original source...
- Katz U, Achiron A, Sherer Y et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6(4): 257-259. Dostupné z DOI: <http://dx.doi.org/10.1016/j.autrev.2006.08.011>.
Go to original source...
Go to PubMed...
- Jolles S, Orange JS, Gardulf A et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol 2015; 179(2): 146-160. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12485>.
Go to original source...
Go to PubMed...